RecruitingNot ApplicableNCT02421705

Visceral Sensitivity in IBD (Irritable Bowel Disease) and IBS (Irritable Bowel Syndrome)

Visceral Sensitivity in IBD and IBS: Role of Inflammation, Immune Activity and Genetic Factors

Sponsor

KU Leuven

Enrollment

99,999,999 participants

Start Date

Feb 1, 2010

Study Type

INTERVENTIONAL

Conditions

Healthy (Controls)IBS Ulcerative Colitis, Active Ulcerative Colitis, Remission (3a: With IBS Symptoms, 3b: Without IBS Symptoms)Crohn's Disease, Active Crohn's Disease, Remission (6a: With IBS Symptoms, 6b: Without IBS Symptoms)

Summary

Aim: More insight in pathogenesis of IBS and IBD. Samples are collected in context of an European research project.

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Inclusion Criteria18

For group 1: IBS
Irritable Bowel Syndrome (IBS) (ROME III criteria)
No obvious organic explanation for the IBS symptoms
Medication which affects the gastrointestinal motility or perception should be stopped at least 24 hours before the study
Group 2: active ulcerative colitis 1. diagnosis of ulcerative colitis (Confirmed by at least one sigmoidoscopy) 3. Medication which affects the gastrointestinal motility or perception should be stopped at least 24 hours before the study
Group 3: ulcerative colitis in remission (3a: with IBS symptoms, 3b: without IBS symptoms)
diagnosis of ulcerative colitis (Confirmed by at least one sigmoidoscopy)
remission is confirmed by at least one sigmoidoscopy
Medication which affects the gastrointestinal motility or perception should be stopped at least 24 hours before the study
Only for group 3a:
Rome III criteria for IBS
Group 4: Healthy controls No abdominal (pain) complaints.
Group 5: active Crohn's disease
\. diagnosis of Crohn's disease (Confirmed by at least one sigmoidoscopy) 3. Medication which affects the gastrointestinal motility or perception should be stopped at least 24 hours before the study
Group 6: Crohn's disease in remission (6a: with IBS symptoms, 6b: without IBS symptoms)
diagnosis of Crohn's disease (Confirmed by at least one sigmoidoscopy)
remission is confirmed by at least one sigmoidoscopy
Medication which affects the gastrointestinal motility or perception should be stopped at least 24 hours before the study

Exclusion Criteria3

For all groups:
co-morbidity: severe kidney- and/or liver disease or thyroid abnormalities and impaired clotting
Abdominal chirurgy (except for an uncomplicated appendectomy)

Interventions

OTHERSample collection

Collection of blood, feces samples, sample of nasal mucosa and biopsies (rectum and colon descendens), questionnaires and performance of rectal sensitivity measurement (barostat), MR scan of brain and transit measurement of colon